- Stock Market Live News Today: Nifty, Sensex gain over 2% each; bank, metal stocks shine
- RBI Monetary Policy Review: Top 20 statements from Governor Shaktikanta Das' MPC address
- 5G rollout: Xiaomi India shares big update on data packs, plans, bundled offers | Interview
- RBI Monetary Policy: Offline Payment Aggregators come under regulatory purview; on parity now with online peers
- Twitter shares update to make video experience better - Step-by-step guide
Dr Reddy's Laboratories
Dr Reddy’s Lab share price cracks nearly 5% amid lower-than-expected Q1 earnings – know what brokerages say
Fri, Jul 29, 2022
The pharma major reported poor performance on the margins front as well as weak US and Europe sales during the June-end quarter of the financial year 2022-23 (Q1FY23), brokerages believe.
More >
Dr Reddy's Q4 Results: PAT down 76% YoY on impacted by impairment charges; company announces dividend of Rs 30
Thu, May 19, 2022
Dr Reddy's Laboratories Limited reported a 76 per cent declne in its net profit at Rs 88 cr for the quarter ended 31 December. The Profit After Tax (PAT) reported by the company in the corresponding quarter in the year-ago period stood at Rs 362.4 cr
More >
Technical Check: After forming a double bottom pattern Divi’s Laboratories eyes 20% upside in next 6-9 months
Fri, Mar 25, 2022
Divi’s Laboratories Ltd has risen nearly 30 per cent in the last one year compared to 20 per cent upside seen in the Nifty50 in the same period, and the technical charts suggest that momentum is likely to continue
More >
8 Nifty50 stocks including HDFC twins, Dr Reddy’s, UltraTech, HUL hit 52-week lows; here is what brokerage opines
Fri, Mar 04, 2022
Similarly, total 26 stocks from the Nifty500 index such as Ashok Leyland, Apollo Tyres, Ramco Cement, Dalmia Bharat, JK Cements, Kansai Nerolac and SBI Cards and Payment Services among others hit their respective 52-week lows
More >
Buy, Sell or Hold: What should investors do with Maruti Suzuki, HDFC and Dr Reddy’s Laboratories?
Thu, Mar 03, 2022
Stocks that were in focus include Maruti Suzuki that closed with losses of over 6 per cent, HDFC Ltd fell nearly 4 per cent and Dr Reddy’s Laboratories was down more than 5 per cent on Wednesday
More >
Outlook 2022: Pharma, healthcare sector looks to sustain momentum, say industry leaders
Thu, Dec 23, 2021
Organisation of Pharmaceutical Producers of India (OPPI) Director-General K G Ananthakrishnan told PTI that it is crucial for the industry to further build momentum towards the gains secured over the course of the pandemic which will help it carve a niche in the global pharma value chain.
More >
Sanjiv Bhasin picks these two stocks for gains- check target price, stop loss, other details
Wed, Oct 27, 2021
In conversation with Anil Singhvi, Managing Editor at Zee Business, Sanjiv Bhasin, Director-IIFL Securities Ltd picked two stocks that is Dr Reddy's Laboratories Ltd and Dalmia Bharat Ltd for profit booking.
More >
Dr Reddy’s share price plummets near 14% in two sessions amid THIS development
Wed, Jul 28, 2021
Dr Reddy’s Laboratories shares continued to decline for the second straight session, it fell around 14 per cent to Rs 4667 a share, day’s low level from Rs 5409 apiece Monday’s close. The company on Tuesday reported lower-than-expected earnings in the first quarter of the financial year 2021-22.
More >
Brokerages divided over Dr Reddy’s prospects as company disappoints street - Check Revised Ratings, Target Price
Wed, Jul 28, 2021
After reporting lower-than-expected first-quarter results, the brokerages are divided on Dr Reddy’s Laboratories prospects, However, the majority of them are maintaining a Neutral or an Underperform ratings on this stock.
More >
Dr Reddy’s posts lower-than-expected Q1 results; stock tanks 8% - Details investors should know
Tue, Jul 27, 2021
The pharmaceutical major Dr Reddy’s Laboratories on Tuesday reported a 1 per cent decline in the consolidated net profit to Rs 571 crore in the first quarter of the financial year 2021-2022. The company had posted Rs 579 crore in the same period a year ago (Q1FY21).
More >
